The EMA relocation: Brexit and the UK's pharmaceutical industry
The 1st July marks six months until the European Medicines Agency (EMA) relocates from London, UK to Amsterdam, the Netherlands, in response to the UK’s decision to withdraw from the European Union. Despite the looming deadline, the EMA has given little indication of procedure beyond 30 March 2019, leading to uncertainty throughout the UK pharmaceutical industry that could negatively affect patients.
Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry.
Thomas Beck, senior vice president, quality management at Recipharm, spoke to Manufacturing Chemist and PharmExec to comment on the impact Brexit will have on the pharmaceutical industry in Europe, including the lack of guidance provided by the EMA regarding the future of the UK sector.
For full articles see: